Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis

Published:2020 Issue:4 Volume:5 Page:e000842
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Brandão Mariana^ORCID,Maurer Christian^ORCID,Ziegelmann Patricia Klarmann^ORCID,Pondé Noam F.^ORCID,Ferreira Arlindo^ORCID,Martel Samuel^ORCID,Piccart Martine,de Azambuja Evandro^ORCID,Debiasi Márcio^ORCID,Lambertini Matteo^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference82 articles.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the median: Estimating survival times for patients starting endocrine therapy for estrogen receptor‐positive, metastatic breast cancer from recent randomized trials;Asia-Pacific Journal of Clinical Oncology;2024-06-16

2. A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer;BMC Medicine;2024-01-12

3. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis;BMC Cancer;2023-08-31

4. Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report;Medicine;2023-06-16

5. Advances in Endocrine Therapy for Breast Cancer;Advances in Clinical Medicine;2023